NCT04238715 2026-03-02
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
Eisai Inc.
Phase 2 Completed
Clinical Trials
8 trialsNCT03822117 2025-11-04
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Incyte Corporation
Phase 2 Terminated
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT04962867 2025-10-03
NCCH2006/MK010 Trial (FORTUNE Trial)
National Cancer Center, Japan
Phase 2 Recruiting
NCT02872714 2025-08-14
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Incyte Corporation
Phase 2 Completed
NCT02924376 2025-08-14
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Incyte Corporation
Phase 2 Completed
NCT05253807 2025-08-05
FIGHT-210
Incyte Corporation
Phase 2 Completed
NCT02699606 2025-04-27
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Janssen Research & Development, LLC
Phase 2 Completed